These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36845017)

  • 1.
    Zhang W; Liao Y; Liu C; Liu L; Zhou X
    Dis Markers; 2023; 2023():6729717. PubMed ID: 36845017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KNSTRN Is a Prognostic Biomarker That Is Correlated with Immune Infiltration in Breast Cancer and Promotes Cell Cycle and Proliferation.
    Zhang W; Xiao Y; Zhou Q; Zhu X; Zhang Y; Xiang Q; Wu S; Song X; Zhao J; Yuan R; Xiao B; Li L
    Biochem Genet; 2024 Oct; 62(5):3709-3739. PubMed ID: 38198023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NamiRNA-mediated high expression of KNSTRN correlates with poor prognosis and immune infiltration in hepatocellular carcinoma.
    Jin L; Zhang X; Fan M; Li W; Zhang X
    Contemp Oncol (Pozn); 2023; 27(3):163-175. PubMed ID: 38239867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Expression of
    Deng P; Zhou R; Zhang J; Cao L
    J Cancer; 2021; 12(11):3239-3248. PubMed ID: 33976733
    [No Abstract]   [Full Text] [Related]  

  • 5. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
    Liu C; Zhang W; Zhou X; Liu L
    Front Immunol; 2022; 13():983490. PubMed ID: 36618420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The circadian rhythm key gene
    Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
    Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
    Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
    Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer analysis: SPAG5 is an immunological and prognostic biomarker for multiple cancers.
    Gao X; Bu H; Gao X; Wang Y; Wang L; Zhang Z
    FASEB J; 2023 Oct; 37(10):e23159. PubMed ID: 37650687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers.
    Qi J; Wu G; He M; Xu Y; Yang Z; Ding L; Wang Y; Zhang Z
    Aging (Albany NY); 2024 Jan; 16(2):1879-1896. PubMed ID: 38261737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
    Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
    Front Immunol; 2022; 13():844736. PubMed ID: 35592314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
    Zhong A; Chen T; Xing Y; Pan X; Shi M
    Front Immunol; 2021; 12():758648. PubMed ID: 34745134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
    Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
    Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Chen L; Lin J; Lan B; Xiong J; Wen Y; Chen Y; Chen CB
    Comput Math Methods Med; 2022; 2022():5851755. PubMed ID: 36510584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
    Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
    Front Immunol; 2022; 13():837512. PubMed ID: 35401558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer analysis reveals NUP37 as a prognostic biomarker correlated with the immunosuppressive microenvironment in glioma.
    He Y; Li J; Shen L; Zhou H; Fei W; Zhang G; Li Z; Wang F; Wen Y
    Aging (Albany NY); 2022 Jan; 14(2):1033-1047. PubMed ID: 35093934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.
    Zhu C; Wang S; Du Y; Dai Y; Huai Q; Li X; Du Y; Dai H; Yuan W; Yin S; Wang H
    BMC Gastroenterol; 2022 Oct; 22(1):437. PubMed ID: 36253721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.